Additional value of PCA3 density to predict initial prostate biopsy outcome.

Area of Science:

• Urology
• Oncology
• Biomarker Research

Background:

• Prostate cancer (PCa) detection relies on biopsies, but predicting outcomes remains challenging.
• Prostate-specific antigen (PSA) density (PSAD) and PCA3 score are used, but their predictive accuracy can be limited.
• PCA3 density (PCA3D), a ratio of urinary PCA3 score to prostate volume, has emerged as a potential tool.

Purpose of the Study:

• To evaluate the diagnostic performance of PCA3D in predicting the outcome of initial prostate biopsies.
• To compare the specificity of PCA3D against PCA3 score and PSAD.
• To assess PCA3D's utility in guiding biopsy decisions for patients at risk of prostate cancer.

Main Methods:

• A cohort of 595 patients undergoing initial prostate biopsy provided serum and urine samples.
• Urinary PCA3 scores, prostate volume, PSA, and PSAD were measured prior to biopsy.
• Multivariate logistic regression and decision curve analyses were employed to evaluate marker performance.

Main Results:

• PCA3D demonstrated superior specificity (76%) compared to PCA3 score.
• A PCA3D cutoff of 1 indicated a 70% risk of a positive biopsy, versus 29% for PCA3D < 1.
• Using a PCA3D cutoff of 0.5 could have avoided biopsies in 52% of patients without PCa, missing 15% of any PCa.
• Decision curve analysis identified PSAD as the best predictor of Gleason score, while PCA3D best predicted invaded cores.

Conclusions:

• PCA3D offers significantly improved specificity over PSA, PSAD, and PCA3 for predicting initial biopsy outcomes.
• PCA3D functions as a simple mini-nomogram, with a PCA3D > 1 suggesting a high likelihood (70%) of a positive biopsy.
• PCA3D shows promise as an effective tool for refining prostate cancer biopsy decision-making.